Bristol-Myers Squibb Licenses Flamel’s Basulin®
By Business Review Editor
Pharma Deals Review: Vol 2003 Issue 40 (Table of Contents)
Published: 3 Oct-2003
DOI: 10.3833/pdr.v2003.i40.859 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Bristol-Myers Squibb and Flamel entered into licensing agreement to develop and commericalize Flamel’s Basulin®, unmodified human insulin which is in phase II clinical trials for treating Diabetes mellitus...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS